Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $648.97K up 1081455% from its previous closing price of $15.08. In other words, the price has increased by $1081455 from its previous closing price. On the day, 1.08 million shares were traded. SYRE stock price reached its highest trading level at $15.2748 during the session, while it also had its lowest trading level at $14.68.
Ratios:
For a deeper understanding of Spyre Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.06 and its Current Ratio is at 8.06. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 08, 2025, initiated with a Outperform rating and assigned the stock a target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.
On September 04, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $45.Wedbush initiated its Outperform rating on September 04, 2024, with a $45 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’24 when Albers Jeffrey W. sold 6,700 shares for $36.76 per share. The transaction valued at 246,313 led to the insider holds 27,360 shares of the business.
Albers Jeffrey W. sold 300 shares of SYRE for $10,929 on Oct 25 ’24. The Director now owns 34,060 shares after completing the transaction at $36.43 per share. On Oct 25 ’24, another insider, SESSIONS, LLC, who serves as the Director of the company, bought 7,000 shares for $33.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 905907520 and an Enterprise Value of 496906944.
Stock Price History:
The Beta on a monthly basis for SYRE is 2.73, which has changed by -0.38052005 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.26, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 0.93%, while the 200-Day Moving Average is calculated to be -33.65%.
Shares Statistics:
For the past three months, SYRE has traded an average of 648.97K shares per day and 635200 over the past ten days. A total of 60.28M shares are outstanding, with a floating share count of 51.32M. Insiders hold about 14.97% of the company’s shares, while institutions hold 99.38% stake in the company. Shares short for SYRE as of 1748563200 were 12090208 with a Short Ratio of 18.63, compared to 1745971200 on 12553112. Therefore, it implies a Short% of Shares Outstanding of 12090208 and a Short% of Float of 25.72.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
